

Postprandial Hepatic Lipid Metabolism Requires Signaling through Akt2 Independent of the Transcription Factors FoxA2, FoxO1, and SREBP1c

Min Wan,¹ Karla F. Leavens,¹ Danish Saleh,¹ Rachael M. Easton,^{1,6} David A. Guertin,^{2,3,4,5} Timothy R. Peterson,^{2,3,4,5} Klaus H. Kaestner,¹ David M. Sabatini,^{2,3,4,5} and Morris J. Birnbaum^{1,*}

¹The Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania, Philadelphia, PA 19104, USA

²Whitehead Institute of Biomedical Research

³Howard Hughes Medical Institute

⁴Department of Biology

⁵Koch Center for Integrative Cancer Research

Massachusetts Institute of Technology, Cambridge, MA 02139, USA

⁶Present address: CSL Behring, 1020 First Avenue, P.O. Box 61501, King of Prussia, PA 19406, USA

*Correspondence: birnbaum@mail.med.upenn.edu

DOI 10.1016/j.cmet.2011.09.001

SUMMARY

Under conditions of obesity and insulin resistance, the serine/threonine protein kinase Akt/PKB is required for lipid accumulation in liver. Two forkhead transcription factors, FoxA2 and FoxO1, have been suggested to function downstream of and to be negatively regulated by Akt and are proposed as key determinants of hepatic triglyceride content. In this study, we utilize genetic loss of function experiments to show that constitutive activation of neither FoxA2 nor FoxO1 can account for the protection from steatosis afforded by deletion of Akt2 in liver. Rather, another downstream target positively regulated by Akt, the mTORC1 complex, is required in vivo for de novo lipogenesis and *Srebp1c* expression. Nonetheless, activation of mTORC1 and SREBP1c is not sufficient to drive postprandial lipogenesis in the absence of Akt2. These data show that insulin signaling through Akt2 promotes anabolic lipid metabolism independent of Foxa2 or FoxO1 and through pathways additional to the mTORC1-dependent activation of SREBP1c.

INTRODUCTION

Insulin is the primary hormone responsible for coordinating the metabolic response to nutrient intake. Following a meal, insulin suppresses the hepatic glucose production that provides the brain substrate during fasting and directs ingested nutrients into long-term energy stores. In particular, insulin promotes triglyceride (TG) synthesis and storage utilizing dietary fatty acids and induces de novo lipogenesis in liver and adipose tissue. Much of this synchronized metabolic response is thought to be mediated by hormone-dependent reduction in the transcription of gluconeogenic genes, such as *glucose-6-phosphatase*,

catalytic subunit (G6pc), and *cytosolic phosphoenolpyruvate carboxykinase 1 (Pck1)*, and activation of lipogenic gene expression via the master regulator *sterol regulatory element-binding transcription factor 1c (Srebp1c)* (Argaud et al., 1996; Horton et al., 2002; O'Brien et al., 2001). Thus, the transcriptional targets of the insulin signaling pathway are of considerable interest.

The serine/threonine kinase Akt (also known as protein kinase B, PKB) is now well-established as a major mediator of the metabolic actions of insulin (Whiteman et al., 2002). Akt2 is the predominant isoform in the insulin-responsive tissues like liver, muscle, and adipose tissue (Cho et al., 2001). Akt2 knockout mice are “diabetic,” whereas liver-specific disruption of the *Akt2* gene has mild effects on glycemia but more dramatic effects on lipogenic gene expression and steatosis in obese, insulin-resistant mice (Cho et al., 2001; Leavens et al., 2009). The canonical nuclear target of Akt, established in worms and flies as well as vertebrates, is the transcription factor Foxhead box O (FoxO) (Gross et al., 2009). Akt phosphorylates and inhibits the transcriptional activity of FoxO at least in part by promoting its exclusion from the nucleus (Durham et al., 1999; Guo et al., 1999; Nakae et al., 1999; Rena et al., 1999; Tang et al., 1999). There are now considerable data implicating FoxO1 as an intermediate in the pathway by which insulin through Akt suppresses hepatic gluconeogenic gene expression and glucose output (Haeusler et al., 2010b; Li et al., 2007; Liu et al., 2008; Matsumoto et al., 2007; Nakae et al., 2001; Puigserver et al., 2003; Qu et al., 2006).

In contrast to the consensus of opinion regarding the role of FoxO1 in the control of gluconeogenic gene expression, its contribution to regulation of hepatic lipid metabolism remains unclear. In some studies, expression of a constitutively active FoxO1 in liver induces *Srebp1c* expression and hepatic TG accumulation, though others have not found this response; in addition, FoxO1 inhibits TG secretion (Matsumoto et al., 2006; Zhang et al., 2006). In contrast, Kamagate et al. reported that FoxO1 is necessary and sufficient to promote hepatic very-low-density lipoprotein-associated TG (VLDL-TG) production and hypertriglyceridemia via its regulation of *microsomal TG transfer protein (MTP)*, and further proposed that this pathway accounts for

elevated serum lipids in insulin-resistant states (Kamagate et al., 2008). Loss-of-function approaches to understand the contribution of FoxO1 to lipogenic gene expression have yielded few striking results, though its ablation in streptozotocin (STZ)-induced diabetes increases serum TG and VLDL-TG secretion (Haeusler et al., 2010a). Deletion of *Foxo1* in *insulin receptor substrate 1* and *2* (*IRS1* and *IRS2*) double-knockout mouse livers partially rescues the deficit in VLDL-TG secretion (Dong et al., 2008). Ablation of all three FoxO isoforms in liver leads to hepatic steatosis, potentially through regulating the expression of *nicotinamide phosphoribosyltransferase* (*Nampt*) and consequently NAD^+ levels (Tao et al., 2011). Thus, there persists considerable uncertainty concerning the physiological role of FoxO1 in controlling hepatic lipid metabolism.

Another forkhead family transcription factor, FoxA2, has been implicated in the control of hepatic lipid metabolism by insulin. Like FoxO, FoxA2 is phosphorylated by Akt, thereby leading to exclusion from the nucleus and inhibition of transcriptional activity, though some investigators have found that FoxA2 resides in nuclei constitutively and does not respond to different nutritional conditions (Wolfrum et al., 2004; Zhang et al., 2005). Expression of a constitutively active FoxA2 in liver of obese mice leads to a phenotype much like a deficiency of insulin signaling, i.e., increased fatty acid oxidation and TG secretion and reduced hepatic TG content (Wolfrum et al., 2004; Wolfrum and Stoffel, 2006). However, the role of FoxA2 in insulin action has been challenged; mice with liver-specific deletion of *FoxA2* demonstrate impaired bile acid metabolism but no alterations in hepatic or serum TG (Bochkis et al., 2008).

It has long been known that a major target of insulin signaling in the regulation of hepatic lipid metabolism is another transcription factor, SREBP1c, a member of the basic helix-loop-helix leucine-zipper family (Ferre and Foulle, 2010; Horton et al., 2002). Both transcription and posttranslational processing of SREBP1c to its transcriptionally active form are stimulated by insulin signaling through Akt, contributing to postprandial increases in de novo lipogenesis (Chakrabarti et al., 2010; Fleischmann and Iynedjian, 2000; Leavens et al., 2009; Li et al., 2010; Porstmann et al., 2005, 2008). SREBP1c translocates to the Golgi complex where it is proteolyzed, liberating an amino-terminal fragment that activates its own expression as well as that of a set of lipogenic enzymes including *fatty acid synthase* (*Fasn*), *acetyl-Coenzyme A carboxylase* (*Acc*), *ATP citrate lyase* (*Acl*), and *glycerol-3-phosphate acyltransferase* (*Gpat*) (Horton et al., 2002; Postic and Girard, 2008). Insulin's ability to promote *Srebp1c* expression depends on the mammalian target of rapamycin complex 1 (mTORC1), as knockdown of an essential component of mTORC1, Raptor (regulatory-associated protein of mTOR), in multiple tissue culture cell lines significantly blunts insulin or Akt-stimulated expression of *Srebp1c* and its targets (Chakrabarti et al., 2010; Duvel et al., 2010; Porstmann et al., 2008). In primary hepatocytes, rapamycin prevents the insulin-dependent induction of *Srebp1c*, but not the reduction in *Pck1*, consistent with the idea that distinct transcriptional targets mediate the effect of insulin on gluconeogenic and lipogenic gene expression (Li et al., 2010).

The goal of the experiments reported herein is to test the dependency of these three transcriptional pathways as downstream targets linking insulin signaling to control of hepatic TG

content and de novo lipogenesis in mice. We have taken a genetic approach to address the epistatic relationship between Akt and its downstream candidate nuclear targets. If inhibition of FoxO1 or FoxA2 were critical to insulin signaling, then the loss in hormone action that accompanies deletion of *Akt2* in liver would be reversed by concomitant deletion of the target transcription factor. If Akt2 promotes de novo lipogenesis in liver via mTORC1, both its activity and *Srebp1c* expression would be decreased upon deletion of *Akt2* in liver. Thus, we ablated *Akt2* expression in liver by tissue-specific homologous recombination alone or simultaneously with either FoxA2 or FoxO1, and analyzed lipid metabolism. Neither FoxA2 nor FoxO1 is downstream of Akt2 in the control of hepatic lipid accumulation, but rather FoxO1 reduces hepatic TG content upstream of or via a parallel pathway to Akt2. We then tested the requirement and sufficiency of activation of mTORC1 for de novo lipogenesis. We found that mTORC1 was required for *Srebp1c* expression and de novo lipogenesis, but, when hepatic *Akt2* was deleted, activation of mTORC1 and SREBP1c was insufficient to drive de novo lipogenesis following a high-carbohydrate meal.

RESULTS

Akt2 Regulates Hepatic TG Accumulation Independent of FoxA2

It has been proposed that insulin inhibits FoxA2 via Akt-dependent phosphorylation and nuclear exclusion, controlling lipid export, fatty acid oxidation, and accumulation of TG in the liver (Wolfrum et al., 2004, 2008; Wolfrum and Stoffel, 2006). We generated mice lacking both Akt2 and FoxA2 in liver by breeding *Akt2*^(loxP/loxP);*FoxA2*^(loxP/loxP) mice to AFP-Cre, which is expressed exclusively in liver (Zhang et al., 2005). As shown in Figure 1A, we achieved essentially complete deletion of *Akt2* in both *Akt2*^(loxP/loxP) and *Akt2*^(loxP/loxP);*FoxA2*^(loxP/loxP) mice. FoxA2 protein levels were also greatly reduced in both *FoxA2* single-knockout and *Akt2*, *FoxA2* double-knockout hepatocytes (Figure 1A). Mice of all four genotypes were submitted to glucose tolerance tests, which showed indistinguishable rates of glucose disposal (see Figure S1A available online). In addition, there were no significant changes in serum insulin or TG levels from either fed or overnight-fasted mice lacking Akt2, FoxA2, or both in liver (Figures S1B and S1C). Adipose tissue mass was the same among the mice of all four genotypes (Figure S1D).

The TG content in livers deficient in Akt2, FoxA2, or both was unchanged compared to wild-type controls when assayed in mice under chow-fed conditions (Figure 1B). Akt2 is required for accumulation of liver TG under some situations that induce hepatic steatosis, and expression of a constitutively active FoxA2 reduces hepatic TG accumulation in *leptin*-deficient (*ob/ob*) mice (Leavens et al., 2009; Wolfrum et al., 2004; Wolfrum and Stoffel, 2006). To address the question of whether endogenous FoxA2 is responsible for the reduction in hepatic TG in livers deficient in Akt2, mice lacking Akt2, FoxA2, or both in liver were fed a high-fat diet (HFD) for 3 months. Glucose tolerance tests were indistinguishable among the four genotypes (Figure S2A), as were serum insulin and TG levels under both fasting and fed conditions (Figures S2B and S2C). Loss of Akt2 in livers trended to a decrease of hepatic TG accumulation relative to wild-type controls after HFD feeding, and this was unaffected by deletion




Figure 1. Akt2 Regulates Hepatic TG Accumulation Independent of FoxA2

(A) Western blot detecting deletion of Akt2 and FoxA2 in primary hepatocytes isolated from wild-type controls (CON), *AFP > Cre;Akt2^(loxP/loxP)* (L-Akt2), *AFP > Cre;FoxA2^(loxP/loxP)* (L-FoxA2), and *AFP > Cre;Akt2^{(loxP/loxP);FoxA2^(loxP/loxP)}* (L-Akt2:FoxA2) mice. Two male mice for each genotype were 2 months old and under fed conditions when primary hepatocytes were isolated.

(B) Hepatic TG levels under fed conditions on normal chow in 2-month-old male mice, n = 8–10 for each genotype.

(C) Body weight (left) and hepatic TG levels (right) under fed conditions on HFD. One-month-old male mice were subjected to 3 months of HFD feeding, n = 6–7 for each genotype. The body weight of control mice of comparable age but maintained on normal chow was 26.2 ± 0.4 g. The variance of hepatic TG levels was significant among four different genotypes by one-way ANOVA but did not achieve statistical significance upon pairwise comparison by Tukey's post test; error bars represent SEM.

of *FoxA2* (Figure 1C). These data show that, at least under conditions of diet-induced obesity (DIO), *FoxA2* activity is unlikely to be the cause of the protection from steatosis rendered by removal of Akt2 from liver. These data are also consistent with previous findings challenging the notion of *FoxA2* as a target of insulin signaling (Zhang et al., 2005).

Loss of Akt2 Suppresses Hepatic TG Levels in FoxO1-Deficient Liver

FoxO1, a transcription factor negatively regulated by the insulin/Akt signaling pathway, promotes expression of gluconeogenic genes such as *G6pc* and *Pck1* (Gross et al., 2009). To assess the function of *FoxO1* as a downstream target of Akt2, we derived *Akt2*, *FoxO1* and combined liver-specific double-knockout mice. Akt2 and *FoxO1* protein levels were significantly reduced in *Akt2* and *FoxO1* single-knockout livers, respectively, and in *Akt2*, *FoxO1* double-knockout livers (Figure 2A, left),




Figure 2. Loss of Hepatic Akt2 Decreases TG Accumulation in Liver Independent of FoxO1 under Normal Chow Feeding

(A) Deletion of Akt2 and *FoxO1* in liver from wild-type controls (CON), *AFP > Cre;Akt2^(loxP/loxP)* (L-Akt2), *AFP > Cre;Akt2^{(loxP/loxP);FoxO1^(loxP/loxP)}* (L-Akt2:FoxO1) mice. Three male mice from each group were sacrificed under fed conditions on normal chow, and liver lysates were prepared to blot for Akt2, *FoxO1*, and β-actin (left). Real-time PCR was performed on cDNA prepared from RNA from 2-month-old male mouse livers under fed conditions, n = 3–5 for each genotype (right).

(B) Pyruvate tolerance test (PTT). Two-month-old male mice were fasted overnight and then injected with 2 g/kg body weight pyruvate i.p. Blood glucose was determined at 0, 15, 30, 60, and 120 min after injection; n = 4–8 for each genotype.

(C) Area under curve from PTT. The variance of AUC levels was significant among four different genotypes by one-way ANOVA but did not achieve statistical significance by pairwise comparison using Tukey's post test.

(D) Hepatic TG levels from 2-month-old male mice fed normal chow after overnight fasting; n = 5–7 for each genotype.

(E) Hepatic TG levels from fed, 2-month-old male mice on normal chow, n = 3–5 for each group. *p < 0.05, **p < 0.01 by one-way ANOVA followed by Tukey's post test; error bars represent SEM.

and real-time PCR from either *FoxO1* knockout livers or *Akt2*, *FoxO1* double-knockout livers showed reduction of *FoxO1* mRNA levels compared to either wild-type controls or *Akt2* knockout livers (Figure 2A, right). Under conditions of normal chow feeding, both *AFP > Cre;Akt2^(loxP/loxP)* and *AFP > Cre;FoxO1^(loxP/loxP)* mice demonstrated normal glucose tolerance (Figure S3A). Moreover, serum insulin and TG levels were the same for all four genotypes when assayed under either fasting or fed conditions (Figures S3B and S3C). When challenged with pyruvate, *AFP > Cre;FoxO1^(loxP/loxP)* mice trended to lower levels of blood glucose, as did *AFP > Cre;Akt2^{(loxP/loxP);FoxO1^(loxP/loxP)}* mice. *AFP > Cre;Akt2^(loxP/loxP)* mice did not differ




Figure 3. Loss of Hepatic Akt2 Decreases TG Accumulation in Liver Independent of FoxO1 under HFD Feeding

(A) Glucose tolerance test (GTT). Four-month-old male mice fed a HFD for 3 months were fasted overnight and injected i.p. with 2 g/kg glucose (left). Area under curve was taken from GTT (right); $n = 4-5$ for each genotype.

(B) Fasting and fed serum insulin levels; $n = 4-5$ for each genotype.

(C) Fasting and fed serum TG levels; $n = 4-5$ for each genotype.

(D) Body weight (left) and hepatic TG levels (right) under fed conditions on HFD; $n = 4-6$. Body weight from control mice that were of comparable age but maintained on normal chow was 31.5 ± 1.3 g. The variance of hepatic TG levels was significant among four different genotypes by one-way ANOVA. * $p < 0.05$ by one-way ANOVA followed by Tukey's post test; error bars represent SEM. Abbreviations are as indicated in Figure 2.

sensitivity as assessed by the euglycemic, hyperinsulinemic clamp (Samuel et al., 2006). To investigate the role of FoxO1 as a downstream mediator of Akt's role in metabolism under pathological conditions, we placed the wild-type controls, $AFP > Cre;Akt2^{(loxP/loxP)}$, $AFP > Cre;FoxO1^{(loxP/loxP)}$ and $AFP > Cre;Akt2^{(loxP/loxP);FoxO1^{(loxP/loxP)}}$ mice, on a HFD for 3 months. Glucose tolerance tests were indistinguishable in mice of all four genotypes (Figure 3A). Fasting and fed serum insulin and TG levels were also similar among these same mice (Figures 3B and 3C). However, under fed conditions, loss of hepatic Akt2 in HFD-fed mice trended to a lower TG level in liver, whereas liver TG upon ablation of FoxO1 did not differ from wild-type controls (Figure 3D). Deletion of

FoxO1 concomitant with Akt2 did not reverse the protection from steatosis in $AFP > Cre;Akt2^{(loxP/loxP)}$ mice (Figure 3D), again militating against the idea that FoxO1 regulates lipid metabolism downstream of Akt2.

Loss of Akt2 Decreases Hepatic TG Levels in FoxO1 Knockout Mice after Aurothioglucose Treatment

In DIO, deletion of Akt2 in liver reduces hepatic TG without altering lipogenesis, whereas in *ob/ob* mice protection from steatosis is accompanied by a concomitant reduction in lipogenesis and lipogenic gene expression (Leavens et al., 2009). To study the $AFP > Cre;Akt2^{(loxP/loxP);FoxO1^{(loxP/loxP)}}$ mice under conditions that mimic *ob/ob* mice, we injected mice with aurothioglucose (goldthioglucose, GTG), which causes hypothalamic damage, hyperphagia, and weight gain (Brecher et al., 1965; Marshall and Mayer, 1954). As shown in Figure 4A, 8 weeks after GTG injection, mice of all genotypes displayed significantly increased body weight and hepatic TG levels compared to age-matched controls (compare Figure 4B to Figure 2E). $AFP > Cre;Akt2^{(loxP/loxP)}$ mice trended to lower hepatic TG, while $AFP > Cre;FoxO1^{(loxP/loxP)}$ mice had significantly elevated TG in liver (Figure 4B). Interestingly, concomitant deletion of Akt2 and

from wild-type controls (Figures 2B and 2C). These data are consistent with previously published results that support a model in which FoxO1 regulates glucose output and is downstream of Akt (Matsumoto et al., 2007).

After an overnight fast, $AFP > Cre;Akt2^{(loxP/loxP)}$, $AFP > Cre;FoxO1^{(loxP/loxP)}$ and $AFP > Cre;Akt2^{(loxP/loxP);FoxO1^{(loxP/loxP)}}$ mice had hepatic TG levels indistinguishable from that in wild-type controls (Leavens et al., 2009; Matsumoto et al., 2007) (Figure 2D). Fed $AFP > Cre;FoxO1^{(loxP/loxP)}$ mice displayed increased hepatic TG levels compared to controls and $AFP > Cre;Akt2^{(loxP/loxP)}$ mice, though TG secretion was unaltered (Figure 2E and Figure S4). Surprisingly, the accumulation of liver TG in the $AFP > Cre;FoxO1^{(loxP/loxP)}$ mice was suppressed by concomitant deletion of Akt2 (Figure 2E). Though deletion of FoxO1 leads to a phenotype opposite to that of deletion of Akt2, these data are inconsistent with a model in which Akt2 regulates lipid accumulation through suppression of FoxO1 activity.

Akt2 Regulates Hepatic TG Levels Independent of FoxO1 upon HFD Feeding

Suppression of FoxO1 by shRNA in livers from DIO mice decreases blood glucose and insulin levels and improves insulin




Figure 4. Loss of Hepatic Akt2 Decreases TG Accumulation in Liver Independent of FoxO1 after Aurothiogluucose Treatment

(A) Mice with aurothiogluucose (GTG) injection gained more weight than age-matched not-treated (NT) controls. Male mice were fasted overnight and then injected with 0.3 g/kg bodyweight GTG at 4–5 weeks old, and were maintained on normal chow for 8 weeks before analysis; $n = 4–8$ for each genotype; $*p < 0.05$ by two-way ANOVA followed by Bonferroni's post test.

(B) Hepatic TG levels under fed conditions in mice injected with GTG as described above, $n = 6–10$ for each group. $*p < 0.05$, $**p < 0.01$ by one-way ANOVA followed by Tukey's post test; error bars represent SEM. Abbreviations are as indicated in Figure 2.

FoxO1 led to livers that accumulated TG levels comparable to those in *AFP > Cre;Akt2^(loxP/loxP)* rather than *AFP > Cre;FoxO1^(loxP/loxP)* mice (Figure 4B). This showed that the *Akt2* mutant phenotype was dominant to that of *FoxO1*, which, again, did not support *Akt2* as upstream of *FoxO1*, but rather suggested that *Akt2* regulates hepatic TG levels downstream of or in parallel to *FoxO1*.

Akt2 Is Required for Postprandial De Novo Lipogenesis

In order to address the pathways downstream of *Akt2* that mediate lipid homeostasis, we sought to establish a model more physiological than hypothalamic obesity that would test the dependency of hepatic lipogenesis on *Akt2*. To accomplish this, mice were fasted overnight and then refed a lipogenic high-carbohydrate diet (HCD). As expected, blood glucose and serum insulin levels increased by 1.5 hr after HCD refeeding and remained high through the 12 hr animals were allowed continuous access to food (Figures 5A and 5B). Deletion of *Akt2* in mouse liver did not alter the glucose or insulin levels compared to wild-type controls, indicating the minimal requirement for hepatic *Akt2* in control of postprandial carbohydrate metabolism (Figures 5A and 5B). Liver weights normalized to body weight also increased significantly after 6 hr refeeding in wild-type mice, but this was blunted in *AFP > Cre;Akt2^(loxP/loxP)* mice (Figure 5C). To evaluate the rate of de novo lipogenesis under these conditions, we injected D_2O at the third hour after feeding and analyzed the incorporation of D_2O into liver palmitate 3 hr later, i.e., 6 hr after feeding. During the labeling period, de novo lipogenesis increased about 5-fold compared to that during fasting, and this effect was blunted in the livers lacking *Akt2* (Figure 5D). These data point to a discrepancy between the requirements for *Akt2* in hepatic lipogenesis versus glycemia following a high-carbohydrate meal. Hepatic mRNAs encoding lipogenic enzymes increased after refeeding a high-carbohydrate meal (Figure 5E). Surprisingly, the expression of *Srebp1c* and its targets *Acly* and *Acc* were only minimally if at all reduced in *AFP > Cre;Akt2^(loxP/loxP)* mice, though there was a blunting in the induction of *glucokinase (Gck)* and *Fasn* (Figure 5E). HCD

feeding suppressed *insulin-induced gene 2a (INSIG2a)* expression for at least 6 hr independent of the presence of hepatic *Akt2* (Figure 5E).

To test whether unrestrained activity of *FoxO1* is the major factor responsible for the lack of postprandial de novo lipogenesis and hepatic weight gain in *AFP > Cre;Akt2^(loxP/loxP)* mice, we measured fatty acid synthesis in livers from *AFP > Cre;Akt2^{(loxP/loxP);FoxO1^(loxP/loxP)}* mice. Elimination of *FoxO1* in liver was without effect on the increase in blood glucose evident after ingestion of a HCD (Figure 6A). However, deletion of *FoxO1* in liver appeared to reverse the prevention in hepatic weight gain evident in the *AFP > Cre;Akt2^(loxP/loxP)* livers, much like the suppression of a similar defect in livers lacking *IRS1* and *IRS2* (Figure 6B) (Dong et al., 2008). Deletion of *FoxO1* alone in liver led to a trend for increased de novo lipogenesis following a meal, consistent with the increase in hepatic TG under several conditions (Figures 2E, 4B, and 6C). Unlike liver size, the decrease in lipid synthesis in livers lacking *Akt2* was not reversed by concomitant removal of *FoxO1*; instead, *AFP > Cre;Akt2^{(loxP/loxP);FoxO1^(loxP/loxP)}* livers demonstrated rates of de novo lipogenesis virtually identical to those in *AFP > Cre;Akt2^(loxP/loxP)* livers (Figure 6C). Delivery by adenovirus of a dominant-negative form of *FoxO1* (Nakae et al., 2001) into *AFP > Cre;Akt2^{(loxP/loxP);FoxA2^(loxP/loxP)}* livers also failed to reverse the decreased lipogenesis in *Akt2* null livers (data not shown). These data are consistent with those presented above in which *Akt2* is epistatic to *FoxO1* regarding the control of liver TG content.

mTORC1 Is Required for De Novo Lipogenesis in Mouse Liver

We next turned to the question: since *FoxO1* and *FoxA2* do not appear to function downstream of *Akt2* in lipid homeostasis, what pathway could mediate *Akt2*'s effect on lipogenic gene expression? The most likely answer lies in the recent observation that in primary hepatocytes, insulin utilizes a pathway dependent on mTORC1 to stimulate the processing and expression of SREBP1c, a transcription factor that drives coordinated lipogenic gene transcription (Azzout-Marniche et al., 2000; Chakrabarti et al., 2010; Duvel et al., 2010; Fleischmann and Iyenedjian, 2000; Li et al., 2010; Porstmann et al., 2008). To test the requirement for this pathway in vivo, we injected *raptor^(loxP/loxP)* mice with an adeno-associated virus expressing liver-specific *Cre* recombinase (AAV > *Cre*) or green fluorescent protein (AAV > *GFP*), thus generating hepatic *raptor* knockout mice or controls. As shown in Figure 7A, *raptor* protein levels were substantially reduced in AAV > *Cre;raptor^(loxP/loxP)* mice, and the phosphorylation of an mTORC1 target, ribosomal protein S6 (S6), was not detected, as assayed by reactivity with a phosphospecific antibody (Figure 7A). Expression of the lipogenic genes *Srebp1c*, *Fas*, *Acly*, and *Gpat* were reduced in AAV > *Cre;raptor^(loxP/loxP)* mice, though *Acc* and *Gck* were unchanged under fed conditions (Figure 7B). Most notably, de novo lipogenesis following a high-carbohydrate meal was largely abrogated in liver from AAV > *Cre;raptor^(loxP/loxP)* mice (Figure 7C).

Having established the critical role of mTORC1 in de novo lipogenesis, we then asked whether defects in its expression and posttranslational processing of SREBP1c explained the disturbed lipid metabolism in *AFP > Cre;Akt2^(loxP/loxP)* mice. Following a high-carbohydrate meal, there was an increase in




Figure 5. Akt2 Is Required for De Novo Lipogenesis after HCD Refeeding

(A) Blood glucose levels after HCD refeeding. Mice were prefed with HCD for 2 days, fasted overnight, and re-fed with HCD. Blood glucose was measured at the indicated time points; n = 4–6 for each condition.

(B) Serum insulin levels after HCD refeeding; n = 4–6 for each condition.

(C) Liver weight to body weight ratio after HCD refeeding; n = 4–6 for each condition.

(D) Newly synthesized palmitate. Mice treated as above were injected with 20 μ l/g bodyweight D_2O 3 hours after HCD refeeding. Six hours after refeeding, mice were sacrificed and incorporation of D_2O into palmitate measured in liver; n = 3–5 for each condition.

(E) Lipogenic gene expression after HCD refeeding. Mice were treated as described in (A); n = 4–6 for each condition. Con, wild-type controls; L-Akt2, $AFP > Cre; Akt2^{(loxP/loxP)}$; *p < 0.05, **p < 0.01 by two-way ANOVA followed by Bonferroni's post test; error bars represent SEM.

the phosphorylated form of protein S6 and eukaryotic translation initiation factor 4E-1A-binding protein 1 (4EBP1), which reflects activation of mTORC1 by nutrients and insulin. Sur-

prisingly, this was unchanged in $AFP > Cre; Akt2^{(loxP/loxP)}$ mice (Figure 7D). Both the precursor and the processed form of SREBP1c increased 6 hr after HCD feeding; induction of these




Figure 6. Loss of Hepatic Akt2 Decreases De Novo Lipogenesis Independent of FoxO1

(A) Fasting and refeed blood glucose levels. Two-month-old male mice were placed on HCD for 3 days, fasted overnight, and refeed with HCD for 6 hr. Blood glucose levels were taken at fasting, 3 hr refeeding, and 6 hr refeeding time points, $n = 5-7$ for each genotype, $**p < 0.01$ by two-way ANOVA followed by Bonferroni's post test, error bars represent SEM.

(B) Liver weight to body weight ratio. Mice were as described above. Six hours after refeeding, mice were sacrificed, and body weight and wet liver weight were determined; $n = 5-7$ for each condition, $*p < 0.05$, $**p < 0.01$ by two-way ANOVA followed by Bonferroni's post test, error bars represent SEM.

(C) De novo lipogenesis, $n = 4-7$ for each genotype, $**p < 0.01$ by one-way ANOVA followed by Tukey's post test; error bars represent SEM. Abbreviations are as indicated in Figure 2.

proteins was only slightly reduced in $AFP > Cre;Akt2^{(loxP/loxP)}$ mice (Figure 7E), consistent with the minimal changes in lipogenic gene expression under these conditions (Figure 5E). These results indicated that the defective lipogenesis was unlikely to be attributed to lack of activation of mTORC1 and SREBP1c. Moreover, in the absence of Akt2, stimulation of mTORC1 and SREBP1c are not sufficient to promote de novo lipogenesis following a high-carbohydrate meal (Figures 5D, 5E, 7D, and 7E).

FoxO1 has been suggested to suppress mTORC1 activity by several mechanisms, e.g., stimulating the expression of mTORC1 inhibitors such as *Sestrin3*, *Raptor independent companion of mTOR (Rictor)*, and possibly *Tuberous sclerosis complex 1 (TSC1)* (Chen et al., 2010; Harvey et al., 2008). To ask whether such a mechanism accounts for the suppression of lipid accumulation by FoxO1, we assessed mTORC1 activity in animals lacking hepatic FoxO1. Six hours after ingesting a high-carbohydrate meal, hepatic phospho-S6 was not altered in $AFP > Cre;FoxO1^{(loxP/loxP)}$ or $AFP > Cre;Akt2^{(loxP/loxP)}$, $FoxO1^{(loxP/loxP)}$ mice (Figure 7E). The expression of *Srebp1c*, *Gck*, *Fasn*, *Acc*, *Acly*, and *Sestrin3* was also unchanged in livers from $AFP > Cre;FoxO1^{(loxP/loxP)}$ mice after HCD refeeding (Figure S5). These data argue against mTORC1 as the mediator of hepatic TG accumulation induced by deletion of *FoxO1*.

Insulin-Stimulated Phosphorylation of ATP Citrate Lyase Is Blunted in Akt2-Deficient Livers

To explore other potential mechanisms utilized by Akt2 to regulate lipid metabolism, we examined two other pathways known to modulate hepatic lipogenesis activity responding to insulin signaling. ATP-citrate lyases (ACLY) catalyze the cleavage of cytosolic citrate to oxaloacetate and acetyl-CoA,

the latter a precursor for fatty acid synthesis. The activity of ACLY is regulated transcriptionally as a target of SREBP1c as well as at the posttranslational level by Akt and protein kinase A phosphorylation (Berwick et al., 2002; Horton et al., 2002; Potapova et al., 2000). Insulin injection stimulated phosphorylation of Akt and ACLY, and phosphorylation of both was blunted in livers from $AFP > Cre;Akt2^{(loxP/loxP)}$ mice (Figure S7A). To study this in more detail, hepatocytes were isolated from control and Akt2 KO livers. Again, insulin promoted Akt and ACLY phosphorylation in a dose-dependent manner. Phosphorylation of both was reduced in primary hepatocytes from Akt2-deficient livers, particularly at low concentrations of insulin (Figure S7B). Those data provide an additional pathway potentially dependent on Akt2 for the increase in de novo lipogenesis in liver.

Atypical PKCs (aPKCs) have been reported to be activated by insulin and to promote *SREBP1c* expression in liver (Farese et al., 2005; Matsumoto et al., 2003; Taniguchi et al., 2006). To ask whether aPKC is dependent on Akt2, we measured aPKC phosphorylation and activity in livers from control and $AFP > Cre;Akt2^{(loxP/loxP)}$ mice but found the levels to be indistinguishable (data not shown). However, we were unable to detect increases in hepatic aPKC phosphorylation or activity following insulin injection of control or $AFP > Cre;Akt2^{(loxP/loxP)}$ mice (data not shown).

DISCUSSION

The metabolic disturbances associated with type 2 diabetes mellitus and the metabolic syndrome have been perceived as being due to an inability of insulin to promote effectively its anabolic actions, a condition long referred to as insulin resistance. However, this view has been modified recently with the increasing appreciation that, while the "insulin-resistant" liver displays some features consistent with an inability of insulin to act, most notably an inappropriately high glucose output, its characteristic increased de novo lipogenesis and TG

accumulation more closely resemble a state of augmented insulin sensitivity. The simplest, though by no means only, explanation for this phenomenon is that insulin resistance occurs at a step distal to a bifurcation in insulin signaling, resulting in selective inhibition of the hormone's effect on glucose output, while permitting signaling to lipid metabolism. Work from our laboratory as well as others suggests that this divergence occurs downstream of Akt, and thus the identification of the specific pathways that Akt2 utilizes to regulate metabolism has achieved particular importance (He et al., 2010; Leavens et al., 2009). In this study, we investigated the roles of two proposed Akt target transcription factors, FoxO1 and FoxA2, and an indirect route for control of a third, SREBP1c, which is regulated by mTORC1. Our data show that, whereas suppression of FoxO1 activity is downstream of Akt in the inhibition of hepatic glucose output, phosphorylation of neither FoxO1 nor FoxA2 is likely to mediate insulin's effects on de novo lipogenesis and TG accumulation in liver. Our data also support the notion that mTORC1 is required for maintenance of *Srebp1c* expression and de novo lipogenesis, but its activation is not sufficient to reverse the reduction of de novo lipogenesis coincident with deletion of *Akt2*. Moreover, it is likely that the mechanism by which Akt2 induces lipogenesis after a high-carbohydrate meal is not based on regulation of gene expression by any of the three transcription factors assessed in this study.


Considerable data support a role for FoxO1 in the control of hepatic gluconeogenic genes expression, though there is much less clarity regarding its importance for glycemia and hepatic lipid metabolism. As has been reported, we found that under normal conditions, hepatic deletion of *FoxO1* resulted in an impaired pyruvate tolerance test, in this study independent of *Akt2* (Figures 2B and 2C) (Matsumoto et al., 2007). Inhibition of FoxO1 activity by various techniques in genetically obese and DIO mouse models decreases blood glucose and insulin levels, and reduces hepatic glucose production as assayed by hyperinsulinemic-euglycemic clamp; loss of hepatic *FoxO1* ameliorates fasting hyperglycemia in the STZ-induced diabetic mice (Altomonte et al., 2003; Haeusler et al., 2010a; Kamagate et al., 2008; Nakae et al., 2002; Samuel et al., 2006). These studies suggest that FoxO1 activity contributes significantly to insulin resistance under pathological conditions. However, in our studies, *AFP > Cre;FoxO1^(loxP/loxP)* mice did not demonstrate reduced blood glucose and insulin levels during DIO, perhaps due to the diet employed and/or the mouse strain used (Figures 3A and 3B).

We also found that livers deficient in FoxO1 trended to increased hepatic TG content, as was reported previously after siRNA-mediated knockdown of FoxO1 or ablation of three FoxO isoforms in liver; these data suggest that FoxO1 normally suppresses lipid accumulation in liver (Kamagate et al., 2008; Tao et al., 2011). Nonetheless, the action of Akt2 to promote hepatic lipid accumulation is not mediated by a suppression of FoxO1, as concomitant deletion of both genes leads to a phenotype resembling loss of Akt2 alone (Figures 2E, 4B, and 6C). Rather, FoxO1 signals to TG content by a pathway genetically upstream of or parallel to Akt2. FoxO1 regulates hepatic lipid content during fasting by accelerating TG secretion through increases in *MTP* (Kamagate et al., 2008). However, others have suggested FoxO1 inhibits VLDL-TG secretion in patholog-

ical conditions (Dong et al., 2008; Haeusler et al., 2010a; Matsumoto et al., 2007; Zhang et al., 2006). Fasting hepatic and serum TG levels were not changed in *AFP > Cre;FoxO1^(loxP/loxP)* mice under normal conditions in this study and others (Figure 2D and Figure S3C) (Matsumoto et al., 2007), and no change was found on the rate of TG secretion in *AFP > Cre;FoxO1^(loxP/loxP)* mice (Figure S4). There were no alterations in *AFP > Cre;FoxO1^(loxP/loxP)* mice of serum TG under obese conditions, and *MTP* expression was not changed in *AFP > Cre;FoxO1^(loxP/loxP)* mice during hypothalamic obesity (Figure 3 and Figure S6). These data suggest that changes in TG secretion are not responsible for hepatic TG accumulation in *AFP > Cre;FoxO1^(loxP/loxP)* mice. FoxO1 also modulates mTORC1 activity, which regulates *Srebp1c* levels and lipogenesis (Chen et al., 2010; Duvel et al., 2010; Harvey et al., 2008). However, deletion of *Akt2*, *FoxO1*, or both did not alter phosphorylation of ribosomal protein S6 after HCD refeeding (Figure 7E), suggesting that the pathway by which FoxO1 normally suppresses lipid accumulation is independent of mTORC1.

FoxA2 has been reported to stimulate fatty acid oxidation, increase TG secretion, and reduce hepatic TG accumulation in obese animals (Wolfrum et al., 2004, 2008; Wolfrum and Stoffel, 2006). Much of the data supporting this model are derived from experiments involving expression of constitutively active *FoxA2* in mouse liver, and thus have the potential of off-target effects. Other experiments took advantage of the reduction in nuclear FoxA2 associated with the obese state, during which the liver is likely to have numerous uncharacterized, complicating metabolic alterations. However, other studies found no change to the nuclear localization of FoxA2, even in the extreme case of elevated insulin levels in *ob/ob* mice (Zhang et al., 2005). In loss-of-function studies, liver-specific *FoxA2* knockout mice displayed no abnormality in hepatic TG levels, consistent with the current results (Bochkis et al., 2008). Under normal chow feeding or in mice with DIO, loss of hepatic FoxA2 did not affect serum glucose and insulin or hepatic TG levels (Figures 1B and 1C and Figures S1 and S2). These data are compatible with a model in which inhibition of FoxA2 is not required for Akt2 to regulate hepatic TG accumulation. These results are qualified by the possibility that, in other mouse strains, the requirements for hepatic steatosis might be different.

Recently, mTORC1 has been shown to enhance de novo lipogenesis by regulating *Srebp1c* expression and processing (Chakrabarti et al., 2010; Duvel et al., 2010; Li et al., 2010; Porstmann et al., 2008). The full activation of mTORC1 requires both nutrients and growth factor signaling, which determine cellular location and Akt-dependent activation of the mTORC1 complex, respectively (Sancak et al., 2008, 2010; Sengupta et al., 2010b). In tissue culture cells and primary hepatocytes, insulin/Akt regulates SREBP1c expression and processing and de novo lipogenesis in an mTORC1-dependent manner (Azzout-Marniche et al., 2000; Chakrabarti et al., 2010; Duvel et al., 2010; Fleischmann and Llynedjian, 2000; Li et al., 2010; Porstmann et al., 2008). However, the model of an obligate role for mTORC1 in hepatic lipogenesis has not been tested genetically in vivo. Herein we report that conditional deletion of *raptor* in liver abolished mTORC1 activity, leading to a reduction in the expression of *Srebp1c* and its targets and decreased de novo lipogenesis (Figures 7A–7C). Interestingly, even though *AFP > Cre;Akt2^(loxP/loxP)*



and $AFP > Cre;Akt2^{(loxP/loxP)};FoxO1^{(loxP/loxP)}$ mice exhibit significantly decreased de novo lipogenesis following a high-carbohydrate meal, activation of mTORC1 and SREBP1c were largely unaffected (Figures 5D, 7D, and 7E). These data indicate that mTORC1 activation is not sufficient to induce lipogenesis under these conditions. During the revision of this paper, Yecies et al. reported an mTORC1-independent pathway by which Akt2 signals through *INSIG2a* to promote SREBP1c processing (Yecies et al., 2011). We found no change in the normal decrease in hepatic *INSIG2a* mRNA in $AFP > Cre;Akt2^{(loxP/loxP)}$ mice after HCD refeeding and only a modest reduction in the nuclear form of SREBP1c or expression of its target genes (Figures 5E and 7E). Thus, the mTORC1-independent pathway revealed in this study by liver-specific deletion of *Akt2* does not represent induction of *INSIG2a* and is unlikely to be related to SREBP1c processing or expression. Rather, we propose that the requirement for Akt2 is linked to its role in the posttranslational control of other targets such as ACLY.

Taking these data in aggregate, we suggest that Akt2 promotes hepatic lipid accumulation and de novo lipogenesis independent of FoxA2 and FoxO1. Moreover, activated mTORC1 and SREBP1c and increased lipogenic gene expression is required but not sufficient for postprandial lipogenesis. Thus, our data provide strong support for the notion that nutrients have a direct role in the liver to promote anabolic lipid metabolism by a process dependent on the presence of a functional mTORC1 complex as well as other Akt-dependent signaling pathways.

EXPERIMENTAL PROCEDURES

Animals

The $AFP > Cre;Akt2^{(loxP/loxP)}$, $AFP > Cre;FoxO1^{(loxP/loxP)}$, and $Raptor^{loxP/loxP}$ mice have been described previously (Leavens et al., 2009; Matsumoto et al., 2007; Sengupta et al., 2010a; Zhang et al., 2005). All animals were raised and treated with approval from the University of Pennsylvania IACUC in accordance with National Institutes of Health (NIH) guidelines. Mice were of a 129/FVB/C57BL6 mixed background, and male littermates were used for all studies. In the FoxA2 experiments, the wild-type control group included mice of genotypes $AFP > Cre;Akt2^{loxP/+}$, $FoxA2^{loxP/+}$, and $Akt2^{loxP/LoxP}$; $FoxA2^{loxP/LoxP}$. Mice labeled as $AFP > Cre;Akt2^{(loxP/loxP)}$ included the genotypes $AFP > Cre;Akt2^{loxP/loxP}$; $FoxA2^{loxP/+}$ and $AFP > Cre;Akt2^{loxP/loxP}; FoxA2^{+/+}$. Mice labeled as $AFP > Cre;FoxA2^{(loxP/loxP)}$ included the genotypes $AFP > Cre;Akt2^{loxP/+}$, $FoxA2^{loxP/loxP}$ and $AFP > Cre;Akt2^{+/+}; FoxA2^{loxP/loxP}$. In the FoxO1 experiments, wild-type controls include genotypes $AFP > Cre;Akt2^{loxP/+}$, $FoxO1^{loxP/+}$ and $Akt2^{loxP/LoxP}$; $FoxO1^{loxP/loxP}$. Mice indicated as $AFP > Cre;Akt2^{(loxP/loxP)}$ included the genotypes $AFP > Cre;Akt2^{loxP/loxP}$; $FoxO1^{loxP/+}$ and $AFP > Cre;Akt2^{loxP/loxP}; FoxO1^{+/+}$. Mice labeled as $AFP > Cre;FoxO1^{(loxP/loxP)}$ included the genotypes $AFP > Cre;Akt2^{loxP/+}$; $FoxO1^{loxP/loxP}$ and $AFP > Cre;Akt2^{+/+}; FoxO1^{loxP/loxP}$. In all cases there were no metabolic phenotypes among the pooled genotypes including *Cre* expressed alone. Mice were main-

tained on a normal chow diet (laboratory rodent diet 5001, LabDiet) unless otherwise noted under 12 hr light/dark cycle (7 a.m./7 p.m.) in a barrier facility. When fed with HFD (D12331i, Research Diets), mice were started at an age of 1 month and remained for 3 months.

For aurothiogluconase (GTG, A0606, Sigma Aldrich) treatment, mice were maintained on normal chow. At 5–6 weeks old, mice were fasted for 24 hr and then injected intraperitoneally (i.p.) with one dose of 0.3 g/kg GTG in PBS. After injection, mice were kept fasted for another 20 hr before normal chow diet was freely accessible for the following 2 months. This protocol has been suggested to reduce mortality caused by GTG injection in mice (Brecher et al., 1965).

For acute excision of Raptor in liver, the adeno-associated virus was generated by Viral Vector Core at University of Pennsylvania. GFP or Cre recombinase was driven by a liver-specific promoter, *thyroxine-binding globulin* (*TBG*) promoter. Mice were injected postorbitally at a dosage of 1.0×10^{11} gc virus diluted in PBS at 6 weeks of age and maintained on normal chow for another 2 weeks before analysis.

Metabolic Measurement

Blood glucose, serum insulin, and hepatic and serum TG levels were measured as described before (Leavens et al., 2009). For experiments involving fasting, mice were deprived of food overnight. For “fed” measurements, mice were reared on designated diet ad libitum before blood and liver samples were taken during the morning between 8 and 10 a.m. For glucose and pyruvate tolerance test, mice were fasted overnight followed by i.p. injection of 2 g/kg glucose or pyruvate, and then blood glucose levels were taken at designated time points.

De Novo Lipogenesis

For de novo lipogenesis assay, mice were fed with HCD (D12450B, Research Diets) for 2 days, and then treated as described in the text. Whole blood and liver samples were taken 3 hr after D₂O injection and frozen in liquid nitrogen. Palmitate was isolated and analyzed by using gas chromatography-electron impact ionization mass spectrometry by the Stable Isotope Tracer Kinetic Service Center in the Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania. The absolute amount of newly made palmitate was assumed equivalent to the de novo lipogenesis rate.

TG Secretion Assay

TG secretion assay was performed as described previously (Millar et al., 2005). Mice were fasted overnight and then injected i.p. with 1 g/kg poloxamer 407 (kindly provided by Dr. John S. Millar, University of Pennsylvania). Blood samples were collected at indicated time points and assayed for serum TG.

Statistics

All data are presented as mean \pm SEM. As noted in the figure legends, data were analyzed by using unpaired Student's t test with two-tailed analysis, one-way ANOVA followed by Tukey's post test, or two-way ANOVA followed by Bonferroni's post test.

SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures, one table, Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at doi:10.1016/j.cmet.2011.09.001.

Figure 7. Raptor Is Required for Lipogenic Gene Expression and De Novo Lipogenesis

- (A) Western blot of Raptor knockout livers. $Raptor^{loxP/loxP}$ male mice were maintained on normal chow and injected with either AAV-TBG-GFP (A-GFP) or AAV-TBG-Cre ($AAV > Cre;raptor^{loxP/loxP}$; A-CRE) at 6 weeks of age. Two weeks after virus injection, mice were fasted overnight (fasted) and then refed with normal chow for 4 hr (refed) before sacrifice.
- (B) Lipogenic gene expression under fed conditions; $n = 6-7$ for each condition, * $p < 0.05$; ** $p < 0.01$ by Student's t test; error bars represent SEM.
- (C) De novo lipogenesis, $n = 6-7$ for each condition, ** $p < 0.01$ by Student's t test; error bars represent SEM.
- (D) Western blot for liver samples from wild-type controls and $AFP > Cre;Akt2^{(loxP/loxP)}$ mice after HCD refeeding. Mice were treated as described in Figure 5.
- (E) Western blot for full-length SREBP1 (fSREBP1) and processed SREBP1 (nSREBP1). Liver samples from 24 hr fasted or 6 hr HCD refeeding control or $AFP > Cre;Akt2^{(loxP/loxP)}$ mice were used for blotting full-length SREBP1 and processed SREBP1.
- (F) Western blot for liver samples from wild-type controls (CON), $AFP > Cre;Akt2^{(loxP/loxP)}$ (L-Akt2), $AFP > Cre;FoxO1^{(loxP/loxP)}$ (L-FoxO1), and $AFP > Cre;Akt2^{(loxP/loxP)};FoxO1^{(loxP/loxP)}$ (L-Akt2:FoxO1) mice 6 hr after HCD refeeding. Mice were treated as described in Figure 6C.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health (NIH) grants RO1 DK56886 and PO1 DK49210 to M.J.B., and 1F30 DK081283 to K.F.L. We would like to thank Dr. Domenico Accili of Columbia University for kindly providing us the *FoxO1^{loxP/loxP}* mice, and Dr. John S. Millar for suggestions on de novo lipogenesis assay and TG secretion assay. Deuterium-labeled palmitate levels were measured by the Stable Isotope Tracer Kinetic Service Center in the Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania. The Viral Vector Core of University of Pennsylvania supported by the Diabetes and Endocrinology Research Center (NIH DK-19525) provided viruses and valuable advice.

Received: December 23, 2010

Revised: June 13, 2011

Accepted: September 1, 2011

Published: October 4, 2011

REFERENCES

- Altomonte, J., Richter, A., Harbaran, S., Suriawinata, J., Nakae, J., Thung, S.N., Meseck, M., Accili, D., and Dong, H. (2003). Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. *Am. J. Physiol. Endocrinol. Metab.* **285**, E718–E728.
- Argaud, D., Zhang, Q., Pan, W., Maitra, S., Pilkis, S.J., and Lange, A.J. (1996). Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5'-flanking sequence. *Diabetes* **45**, 1563–1571.
- Azzout-Marniche, D., Becard, D., Guichard, C., Foretz, M., Ferre, P., and Foulle, F. (2000). Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. *Biochem. J.* **350**, 389–393.
- Berwick, D.C., Hers, I., Heesom, K.J., Moule, S.K., and Tavare, J.M. (2002). The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. *J. Biol. Chem.* **277**, 33895–33900.
- Bochkis, I.M., Rubins, N.E., White, P., Furth, E.E., Friedman, J.R., and Kaestner, K.H. (2008). Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. *Nat. Med.* **14**, 828–836.
- Brecher, G., Laqueur, G.L., Cronkite, E.P., Edelman, P.M., and Schwartz, I.L. (1965). The brain lesion of goldthioglucose obesity. *J. Exp. Med.* **121**, 395–401.
- Chakrabarti, P., English, T., Shi, J., Smas, C.M., and Kandror, K.V. (2010). Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. *Diabetes* **59**, 775–781.
- Chen, C.C., Jeon, S.M., Bhaskar, P.T., Nogueira, V., Sundararajan, D., Tonic, I., Park, Y., and Hay, N. (2010). FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. *Dev. Cell* **18**, 592–604.
- Cho, H., Mu, J., Kim, J.K., Thorvaldsen, J.L., Chu, Q., Crenshaw, E.B., 3rd, Kaestner, K.H., Bartolomei, M.S., Shulman, G.I., and Birnbaum, M.J. (2001). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). *Science* **292**, 1728–1731.
- Dong, X.C., Copps, K.D., Guo, S., Li, Y., Kollipara, R., DePinho, R.A., and White, M.F. (2008). Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. *Cell Metab.* **8**, 65–76.
- Durham, S.K., Suwanichkul, A., Scheimann, A.O., Yee, D., Jackson, J.G., Barr, F.G., and Powell, D.R. (1999). FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. *Endocrinology* **140**, 3140–3146.
- Duvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol. Cell* **39**, 171–183.
- Farese, R.V., Sajan, M.P., and Standaert, M.L. (2005). Atypical protein kinase C in insulin action and insulin resistance. *Biochem. Soc. Trans.* **33**, 350–353.
- Ferre, P., and Foulle, F. (2010). Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. *Diabetes Obes. Metab.* **12** (Suppl 2), 83–92.
- Fleischmann, M., and Linedjian, P.B. (2000). Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. *Biochem. J.* **349**, 13–17.
- Gross, D.N., Wan, M., and Birnbaum, M.J. (2009). The role of FOXO in the regulation of metabolism. *Curr. Diab. Rep.* **9**, 208–214.
- Guo, S., Rena, G., Cichy, S., He, X., Cohen, P., and Unterman, T. (1999). Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. *J. Biol. Chem.* **274**, 17184–17192.
- Haeusler, R.A., Han, S., and Accili, D. (2010a). Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. *J. Biol. Chem.* **285**, 26861–26868.
- Haeusler, R.A., Kaestner, K.H., and Accili, D. (2010b). FoxOs function synergistically to promote glucose production. *J. Biol. Chem.* **285**, 35245–35248.
- Harvey, K.F., Mattila, J., Sofer, A., Bennett, F.C., Ramsey, M.R., Ellisen, L.W., Puig, O., and Hariharan, I.K. (2008). FOXO-regulated transcription restricts overgrowth of Tsc mutant organs. *J. Cell Biol.* **180**, 691–696.
- He, L., Hou, X., Kanel, G., Zeng, N., Galicia, V., Wang, Y., Yang, J., Wu, H., Birnbaum, M.J., and Stiles, B.L. (2010). The critical role of AKT2 in hepatic steatosis induced by PTEN loss. *Am. J. Pathol.* **176**, 2302–2308.
- Horton, J.D., Goldstein, J.L., and Brown, M.S. (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J. Clin. Invest.* **109**, 1125–1131.
- Kamagata, A., Qu, S., Perdomo, G., Su, D., Kim, D.H., Slusher, S., Meseck, M., and Dong, H.H. (2008). FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. *J. Clin. Invest.* **118**, 2347–2364.
- Leavens, K.F., Easton, R.M., Shulman, G.I., Previs, S.F., and Birnbaum, M.J. (2009). Akt2 is required for hepatic lipid accumulation in models of insulin resistance. *Cell Metab.* **10**, 405–418.
- Li, X., Monks, B., Ge, Q., and Birnbaum, M.J. (2007). Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. *Nature* **447**, 1012–1016.
- Li, S., Brown, M.S., and Goldstein, J.L. (2010). Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. *Proc. Natl. Acad. Sci. USA* **107**, 3441–3446.
- Liu, Y., Dentin, R., Chen, D., Hedrick, S., Ravnskaer, K., Schenk, S., Milne, J., Meyers, D.J., Cole, P., Yates, J., 3rd., et al. (2008). A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. *Nature* **456**, 269–273.
- Marshall, N.B., and Mayer, J. (1954). Energy balance in goldthioglucose obesity. *Am. J. Physiol.* **178**, 271–274.
- Matsumoto, M., Ogawa, W., Akimoto, K., Inoue, H., Miyake, K., Furukawa, K., Hayashi, Y., Iguchi, H., Matsuki, Y., Hiramoto, R., et al. (2003). PKCdelta in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. *J. Clin. Invest.* **112**, 935–944.
- Matsumoto, M., Han, S., Kitamura, T., and Accili, D. (2006). Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. *J. Clin. Invest.* **116**, 2464–2472.
- Matsumoto, M., Poci, A., Rossetti, L., Depinho, R.A., and Accili, D. (2007). Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. *Cell Metab.* **6**, 208–216.
- Millar, J.S., Cromley, D.A., McCoy, M.G., Rader, D.J., and Billheimer, J.T. (2005). Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. *J. Lipid Res.* **46**, 2023–2028.
- Nakae, J., Park, B.C., and Accili, D. (1999). Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. *J. Biol. Chem.* **274**, 15982–15985.

- Nakae, J., Kitamura, T., Silver, D.L., and Accili, D. (2001). The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. *J. Clin. Invest.* 108, 1359–1367.
- Nakae, J., Biggs, W.H., 3rd, Kitamura, T., Cavenee, W.K., Wright, C.V., Arden, K.C., and Accili, D. (2002). Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. *Nat. Genet.* 32, 245–253.
- O'Brien, R.M., Streeper, R.S., Ayala, J.E., Stadelmaier, B.T., and Hornbuckle, L.A. (2001). Insulin-regulated gene expression. *Biochem. Soc. Trans.* 29, 552–558.
- Porstmann, T., Griffiths, B., Chung, Y.L., Delpuech, O., Griffiths, J.R., Downward, J., and Schulze, A. (2005). PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. *Oncogene* 24, 6465–6481.
- Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leever, S., Griffiths, J.R., Chung, Y.L., and Schulze, A. (2008). SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab.* 8, 224–236.
- Postic, C., and Girard, J. (2008). Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. *J. Clin. Invest.* 118, 829–838.
- Potapova, I.A., El-Maghrabi, M.R., Doronin, S.V., and Benjamin, W.B. (2000). Phosphorylation of recombinant human ATP:citrate lyase by cAMP-dependent protein kinase abolishes homotropic allosteric regulation of the enzyme by citrate and increases the enzyme activity. Allosteric activation of ATP:citrate lyase by phosphorylated sugars. *Biochemistry* 39, 1169–1179.
- Puigserver, P., Rhee, J., Donovan, J., Walkey, C.J., Yoon, J.C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., and Spiegelman, B.M. (2003). Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. *Nature* 423, 550–555.
- Qu, S., Altomonte, J., Perdomo, G., He, J., Fan, Y., Kamagate, A., Meseck, M., and Dong, H.H. (2006). Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. *Endocrinology* 147, 5641–5652.
- Rena, G., Guo, S., Cichy, S.C., Unterman, T.G., and Cohen, P. (1999). Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. *J. Biol. Chem.* 274, 17179–17183.
- Samuel, V.T., Choi, C.S., Phillips, T.G., Romanelli, A.J., Geisler, J.G., Bhanot, S., McKay, R., Monia, B., Shutter, J.R., Lindberg, R.A., et al. (2006). Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. *Diabetes* 55, 2042–2050.
- Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L., and Sabatini, D.M. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science* 320, 1496–1501.
- Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A.L., Nada, S., and Sabatini, D.M. (2010). Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* 141, 290–303.
- Sengupta, S., Peterson, T.R., Laplante, M., Oh, S., and Sabatini, D.M. (2010a). mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. *Nature* 468, 1100–1104.
- Sengupta, S., Peterson, T.R., and Sabatini, D.M. (2010b). Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. *Mol. Cell* 40, 310–322.
- Tang, E.D., Nunez, G., Barr, F.G., and Guan, K.L. (1999). Negative regulation of the forkhead transcription factor FKHR by Akt. *J. Biol. Chem.* 274, 16741–16746.
- Taniguchi, C.M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., Farese, R., Cantley, L.C., and Kahn, C.R. (2006). Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. *Cell Metab.* 3, 343–353.
- Tao, R., Wei, D., Gao, H., Liu, Y., Depinho, R.A., and Dong, X.C. (2011). Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. *J. Biol. Chem.* 286, 14681–14690.
- Whiteman, E.L., Cho, H., and Birnbaum, M.J. (2002). Role of Akt/protein kinase B in metabolism. *Trends Endocrinol. Metab.* 13, 444–451.
- Wolfrum, C., and Stoffel, M. (2006). Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. *Cell Metab.* 3, 99–110.
- Wolfrum, C., Asilmaz, E., Luca, E., Friedman, J.M., and Stoffel, M. (2004). Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. *Nature* 432, 1027–1032.
- Wolfrum, C., Howell, J.J., Ndungo, E., and Stoffel, M. (2008). Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. *J. Biol. Chem.* 283, 16940–16949.
- Yecies, J.L., Zhang, H.H., Menon, S., Liu, S., Yecies, D., Lipovsky, A.I., Gorgun, C., Kwiatkowski, D.J., Hotamisligil, G.S., Lee, C.H., and Manning, B.D. (2011). Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. *Cell Metab.* 14, 21–32.
- Zhang, L., Rubins, N.E., Ahima, R.S., Greenbaum, L.E., and Kaestner, K.H. (2005). Foxa2 integrates the transcriptional response of the hepatocyte to fasting. *Cell Metab.* 2, 141–148.
- Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D.R., Le, J., Klotsas, A., Matika, R., Xiao, X., Franks, R., et al. (2006). FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. *J. Biol. Chem.* 281, 10105–10117.